Post-traumatic stress disorder (PTSD) is a condition with limited effective therapeutic options to date, where 5-HT2A receptor agonists show promise for enhancing cortical plasticity in the brain and ...

For decades, scientists have investigated the neurokinin-1 receptor (NK1R) as a potential target for treating major depressive disorder. Early studies suggested promise, but enthusiasm faded after ...

Cannabidiol (CBD) could become a therapeutic tool to address some of the most frequent and disabling consequences of fetal ...

In April 2025, CMG Pharmaceutical, a subsidiary of CHA Biotech, secured FDA approval for Mezofy (formerly Depipzo), an oral ...

Using a mouse model of fetal alcohol spectrum disorder, researchers found that early, chronic cannabidiol treatment ...

LMNT reports that GLP-1 medications for obesity and diabetes may lead to electrolyte imbalances, highlighting hydration ...

INGREZZA showed a nearly two-fold higher VMAT2 occupancy, consistent with greater potency when compared to AUSTEDO XR (deutetrabenazine) after a single ...

It comes as an Iranian security official says 2,000 people have been killed so far after a crackdown on anti-government protests.

Alto Neuroscience, Inc. ("Alto") , a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the issuance of U.

(NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced updated efficacy and safety results from the ...